Toward Vaccine Equity

Policies must ensure accessibility and affordability for all Though COVID-19 triggered an exceptional crisis with unforeseen and shifting challenges, vaccine manufacturing and supply has seen unprecedented progress worldwide in less than a year.

Toward Vaccine Equity

Though COVID-19 triggered an exceptional crisis with unforeseen and shifting challenges, vaccine manufacturing and supply has seen unprecedented progress worldwide in less than a year. Eleven vaccines are already in clinical use in the countries where they obtained approval,often with emergency or limited authorization.More than 80 additional candidates are in clinical trial and hundreds of candidates are in the pre-clinical phase.